CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases (NEOVASC-CD160)

CHU de Reims

Status: Completed

Conditions: Surgical Retinal

Treatments: Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks

Study type: Observational

Funder types: Other

Identifiers

NCT03940664

2018Ao001

Details and patient eligibility

About

The aims of this study were

• to analyze CD160 expression in both normal and pathological eyes from human adults
• to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Full description

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.

CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Enrollment: 75 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

inclusion criteria :

• Patients with retinal surgery
• Patients who agree to participate to the study
• Major patient

exclusion criteria :

• Patient under law protection
• Minor patient

Trial design

75 participants in 2 patient groups

neovascular group

Description:

patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment

Treatment:

Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks

non-neovascular group

Description:

patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.

Treatment:

Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks